Loading...
Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis
BACKGROUND: Rituximab (RTX), a B cell–depleting anti-CD20 monoclonal antibody, is approved for treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Low immunoglobulin (Ig) levels have been observed surrounding RTX treatment. The association between the degree of Ig d...
Na minha lista:
| Udgivet i: | Clin Kidney J |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5570101/ https://ncbi.nlm.nih.gov/pubmed/28852483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfx014 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|